Cutting-edge innovation that aims to provide the first FDA-approved pharmaceutical solution for diabetic foot ulcer treatment.
Skin Wound Healing Approaches
The Number of Negative Pressure Wound Therapy Types
The Number of Conventional & Smart Dressings Types
The Number of Topical Growth Factors
Approved Pharmaceutical Products
Types of Bioengineered Skin Substitutes
Skin is a physical barrier composed of two primary layers epidermis (superficial) and dermis (underlying) which protects the body against microbial invasions and mechanical, thermal, and radiation injuries, as well as participates in the homeostatic mechanisms for regulation of body temperature and fluids (hydration). When this barrier is breached, treatment of the resultant skin wound can become a potential health-related and therapeutic challenge. Normal healing of a skin wound is a complex, interactive, and coordinated process of cells, proteins, growth factors, and extracellular matrices, whose ultimate goal is to accomplish efficient and effective wound closure. The healing process of a skin wound comprises four sequential, distinct, overlapping, and predictable phases: Hemostasis or phase 1, starts immediately after a skin injury and lasts for minutes to hours; Inflammation or phase 2, starts concomitantly with the hemostasis phase and lasts up to 2 weeks; Proliferation, tissue growth and re-epithelialization or phase 3, starts 2 days after a skin injury and lasts up to 4 weeks; and Remodeling or phase 4, starts 2 weeks after a skin injury and lasts up to several months. The main cell types which actively participate in the wound healing process are polymorphonuclear neutrophils (PMNs), monocytes, and macrophages (phase 2), and endothelial cells, epithelial cells, keratinocytes and fibroblasts (phases 3 and 4). Coordination, timing and transition between the four phases of the wound healing process depends on the differentiation, maturation, and migration rates of these cells. The wound healing process is also a fragile and is susceptible to interruption or failure leading to the formation of hard-to-heal wounds. The timing of a wound re-epithelialization can decide the outcome of the healing. If re-epithelization of a wounded skin area is fast, the healing will result in regeneration, but if re-epithelization is slow, infection of a wound might occur, and a scar will form over weeks, months or years.
To address the problem of non-healing wounds such as diabetic foot ulcers and partial- or full-thickness burn wounds, an effective treatment would first require an agent that inhibits the process of inflammatory response and thereafter accelerates the event of re-epithelialization to achieve wound closure. Second, considering that such wounds are large damaged skin areas that expands horizontally and vertically, such an agent must also be safe and show limited sides effects.
We developed a topical hydrogel technology platform which offers a safe, cost-effective easy to use therapeutic pharmaceutical solution for acute and hard-to-heal wounds. We demonstrated that the application of our topical hydrogel technology to a chronic wound such as a diabetic foot ulcer is a safe and effective therapy for accelerating its healing with no side effects. Our topical hydrogel is a radical novel therapy for accelerating wound healing. The hydrogel formulation technology platform comprises of an FDA-approved biologic as an active pharmaceutical ingredient and proprietary excipients which are generally recognized as safe by the FDA. This innovative formulation is a proprietary method which provides the hydrogel physicochemical properties to withstand harsh and varied environments such as extreme acidity and temperature fluctuations to guarantee long-term stability, biological activities and effectiveness. Our innovative formulation is a matrix viscous hydrogel that boosts the distribution of the active ingredient locally onto cell surfaces of a wound bed thereby focusing its effects on cutaneous cells that participate in the wound healing process and prevents it from exerting random and indiscriminate local effects on the wound. The beneficial effects of our topical hydrogel on wound healing are exploited and protected by Remedor Biomed for wound treatment.
Our topical hydrogel is formulated to act as a first-line treatment following effective wound care. Our hydrogel technology-related products are supplied in multi-use tubes for treatment of non-healing wounds in the clinic or for self-use by the patients at their homes to help them accelerate the healing of their wounds. The products can also be conjugated to current wound standard of care treatments and to existing management practices including cleansing, debridement, offloading, infection control and skin autografts. The hydrogel can be applied topically onto a non-healing wound and its application can be repeated daily up to complete wound closure without sides effect.
For the first time in history, contrary to other pharmaceutical approaches, our topical hydrogel offers a full curative pharmaceutical solution that incorporate safety, effectiveness, affordability and ease-of-use in one product for wound treatment. Our products establish new norms and adds a critical layer to the current management of chronic wounds such as diabetic foot ulcer or a burn injury. Firstly, contrary to all current approaches that target only 1 or 2 phases of the 4 known phases of the wound healing process, our topical hydrogel positively targets all the phases, thereby overcoming the limitations of the existing approaches for chronic wound treatment. Secondly, the active ingredient in our hydrogel is an approved biologic with well-known safety profile.